Xellia Pharmaceuticals

Trending Articles

  1. NICE approves KEYTRUDA as first perioperative immunotherapy for locally advanced head and neck cancer MSD's KEYTRUDA (pembrolizumab) has received NICE approval as a neoadjuvant and adjuvant therapy for resectable LA HNSCC—the first immunotherapy recommended in this...
  2. Destination Russia for new NYK Logistics warehouse Logistics specialist NYK is expanding its market presence with the launch of new warehousing operation in Moscow, Russia.
  3. Pfizer agrees sale of consumer healthcare business to J&J Pfizer Inc has reached an agreement to sell its consumer healthcare business to Johnson & Johnson (J&J) for US$16.6bn (euro13.2bn) in cash.
  4. Pfizer's HYMPAVZI receives positive CHMP opinion for haemophilia A and B patients with inhibitors The EMA's Committee for Medicinal Products for Human Use has recommended expanding the approved indication for Pfizer's HYMPAVZI to include adolescents and adults with...
  5. AstraZeneca's tozorakimab meets primary endpoint in both Phase III COPD trials AstraZeneca has reported positive results from the OBERON and TITANIA Phase III trials, with tozorakimab significantly reducing moderate-to-severe COPD exacerbations compared...

Upcoming event

Making Pharmaceuticals

21–22 April 2026 | Exhibition | Coventry, UK See all

Related Content

Manufacturing

US court lifts modified consent decree on Xellia’s Cleveland facility

The Modified Consent Decree imposed on Xellia's Cleveland facility in 2016 has been vacated, receiving a VAI
Manufacturing

Xellia Cleveland manufacturing facility operational for anti-infectives

In addition to commencing commercial supply, the facility is also preparing ramp-up of its recently installed aseptic bag manufacturing line
Ingredients

Xellia Pharmaceuticals launches additional Vanco Ready doses

Vanco Ready will now cover relevant doses from 500 mg to 2 g in 250 mg increments
Regulatory

Xellia Pharmaceuticals expands approved doses of VANCO READYTM

The drug is universally recognised as a key intervention in the management of sepsi at life-threatening state, as well as other infections
Recruitment

Career Opportunities: Automation Engineer (7243)

Xellia Pharmaceuticals is owned by Novo Holding A/S and is a specialty pharmaceutical company leading in the development, manufacture and supply of anti-infective treatments
Recruitment

Career Opportunities: Global Packaging Manager, Sterile Products (5677)

Xellia Pharmaceuticals is owned by Novo Holding A/S and is a specialty pharmaceutical company leading in the development, manufacture and supply of anti-infective treatments
Recruitment

Career Opportunities: Senior Logistics and Process Engineer (6982)

Xellia Pharmaceuticals is owned by Novo Holding A/S and is a specialty pharmaceutical company leading in the development, manufacture and supply of anti-infective treatments
Subscribe now